With so much at stake, there is no room for compromise. Edwards SAPIEN 3 TAVR helps you:

Deliver outcomes you demand

1%

death or disabling stroke at 1 year in low risk patients1

Perfect the pathway through efficient procedures

80%

of patients discharged the next day1*

Control for the future to continue to meet the emerging needs of new patient populations

100%

successful post-TAVR coronary access (68/68 patients)3

*Study includes both SAPIEN XT and SAPIEN 3 valves.

The valve designed to meet your Higher Standard.

Scroll / swipe side to side to review timeline

*The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure) and multiple pre-specified secondary endpoints.

Clinical Study

25,000+

patients studied in Edwards clinical trials

Real world experience

660,000+

patients treated worldwide with Edwards TAVI valves

Data on file at Edwards Lifesciences.

References:   1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 2. Wood, D.A.; Lauck, S.B.; Cairns, J.A. et al. The Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: The 3M TAVI Study. J Am Coll Cardiol Intv. 2019. 3. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.